A forgotten brain signal reduces Alzheimer’s plaques and inflammation in mice
After decades of research focused on amyloid plaques and tau tangles, a study points to a neglected signalling molecule in the brain — and drugs that target it already exist.
Alzheimer’s disease is defined by two types of protein accumulation: amyloid-beta plaques between neurons, and tau tangles inside them. Nearly all major clinical trials over the past two decades have aimed at clearing or preventing these deposits. Progress was slow and disappointing until recently, when two antibody therapies showed modest effects — though with serious side effects in a significant proportion of patients.
Meanwhile, other research groups are searching for targets further upstream: factors that make the brain vulnerable to the disease, or that could slow its progression without directly attacking the amyloid cascade.
Somatostatin: a neglected signal
Somatostatin is a neuropeptide — a small signalling molecule produced by neurons — best known for its inhibitory effects on hormone release, but also active within the brain itself. In Alzheimer’s patients, somatostatin levels in brain tissue are reduced. This observation was noted decades ago but largely faded from mainstream research attention.
A new study, covered by Lifespan.io, revisited the role of this peptide in a mouse model of Alzheimer’s. Researchers engineered brain cells to overexpress somatostatin genes and measured a range of outcomes. The results were notable: amyloid-beta burden decreased, neuroinflammation — the chronic, low-grade inflammatory activity in brain tissue that both accompanies and amplifies neurodegeneration — fell measurably, and the mice performed better on cognitive and memory tests.
Existing drugs, new application
The finding carries an immediate therapeutic implication. Drugs that affect the somatostatin signalling pathway already exist — analogues are used clinically for other conditions, including certain hormonal disorders and some cancers. That means the route to potential clinical application could be shorter than with an entirely novel molecular target, which typically requires years of safety and pharmacology work from scratch.
But the translation from mouse to human is notoriously unreliable in Alzheimer’s research specifically. Dozens of treatments that looked compelling in rodent models have failed in clinical trials. The question is whether somatostatin signalling operates comparably in the human brain, and whether elevating it over sustained periods is safe — the peptide has effects distributed across the body, not just in neural tissue, which makes targeted delivery a significant challenge.